Review article: short chain fatty acids as potential therapeutic agents in human gastrointestinal and inflammatory disorders

Alimentary Pharmacology and Therapeutics - Tập 48 Số 1 - Trang 15-34 - 2018
Paul Gill1,2, Menno C. van Zelm2, Jane G. Muir1, Peter R. Gibson1
1Department of Gastroenterology, Central Clinical School, Monash University and Alfred Hospital, Melbourne, Vic., Australia
2Department of Immunology and Pathology, Central Clinical School, Monash University and Alfred Hospital, Melbourne, Vic, Australia

Tóm tắt

SummaryBackground

Butyrate, propionate and acetate are short chain fatty acids (SCFA), important for maintaining a healthy colon and are considered as protective in colorectal carcinogenesis. However, they may also regulate immune responses and the composition of the intestinal microbiota. Consequently, their importance in a variety of chronic inflammatory diseases is emerging.

Aims

To review the physiology and metabolism of SCFA in humans, cellular and molecular mechanisms by which SCFA may act in health and disease, and approaches for therapeutic delivery of SCFA.

Methods

A PubMed literature search was conducted for clinical and pre‐clinical studies using search terms: ‘dietary fibre’, short‐chain fatty acids’, ‘acetate’, ‘propionate’, ‘butyrate’, ‘inflammation’, ‘immune’, ‘gastrointestinal’, ‘metabolism’.

Results

A wide range of pre‐clinical evidence supports roles for SCFA as modulators of not only colonic function, but also multiple inflammatory and metabolic processes. SCFA are implicated in many autoimmune, allergic and metabolic diseases. However, translating effects of SCFA from animal studies to human disease is limited by physiological and dietary differences and by the challenge of delivering sufficient amounts of SCFA to the target sites that include the colon and the systemic circulation. Development of novel targeted approaches for colonic delivery, combined with postbiotic supplementation, may represent desirable strategies to achieve adequate targeted SCFA delivery.

Conclusions

There is a large array of potential disease‐modulating effects of SCFA. Adequate targeted delivery to the sites of action is the main limitation of such application. The ongoing development and evaluation of novel delivery techniques offer potential for translating promise to therapeutic benefit.

Từ khóa


Tài liệu tham khảo

10.1136/bmj.f6879

10.1016/S0140-6736(03)13174-1

10.1093/ajcn/77.3.622

10.1079/PNS2003208

10.1093/ajcn/70.5.928

10.1093/jn/116.9.1772

10.1111/apt.13456

10.1111/j.1365-2672.1991.tb02739.x

10.1017/S095442241700004X

10.1038/ajg.2013.63

10.1136/gut.2009.195370

10.1038/284283a0

10.1136/pgmj.60.709.811

10.1136/gut.34.3.386

10.1016/0016-5085(92)90765-Q

10.1016/j.nutres.2008.02.014

10.1111/j.1750-3841.2011.02172.x

10.1073/pnas.1005963107

10.1038/ismej.2010.118

10.1038/ismej.2012.4

10.1111/j.1462-2920.2008.01815.x

10.1017/S0029665114001463

10.1136/gut.34.4.437

10.3945/jn.110.128504

10.1079/PNS2002207

10.1136/gutjnl-2014-307198

10.1172/JCI110079

10.1093/jn/131.10.3098

10.1093/ajcn/62.1.121

10.1128/AEM.72.5.3593-3599.2006

10.1152/ajpgi.00265.2013

10.1186/1471-2180-9-123

10.1128/AEM.70.10.6113-6122.2004

10.1128/AEM.71.7.3692-3700.2005

10.1136/gut.28.10.1221

10.1002/jps.24274

10.1093/ajcn/79.6.1020

10.1017/S0007114510004988

10.1016/j.watres.2016.12.045

10.1136/gut.45.6.840

10.1016/0016-5085(91)90077-X

10.1136/gut.41.2.245

10.1136/gut.38.6.870

10.1152/ajpgi.1998.275.6.G1415

10.1038/ijo.2014.153

10.1136/gutjnl-2014-307913

10.1038/s41598-017-02546-x

10.1136/gut.28.2.166

10.1042/bj1420401

10.1111/j.1530-0277.2002.tb02530.x

10.1016/0009-8981(89)90073-9

10.1042/cs0800177

10.1016/S0026-0495(97)90127-X

Todesco T, 1993, Plasma acetate levels in a group of obese diabetic, obese normoglycemic, and control subjects and their relationships with other blood parameters, Am J Gastroenterol, 88, 751

10.3168/jds.2015-10795

10.1002/9780813820866.ch1

10.1093/ajcn/73.2.374s

10.1016/j.foodchem.2011.02.048

10.1016/S0168-1656(98)00014-5

10.1016/S1874-558X(04)80044-7

10.1016/j.idairyj.2005.10.030

10.1016/0958-6946(95)00028-2

10.1007/BF00395937

10.1016/j.foodres.2012.02.012

10.1093/jn/121.11.1787

10.1007/s003940070028

10.1016/0016-5085(91)90008-9

10.1074/jbc.C400059200

10.1152/ajpgi.00308.2012

10.1002/jcb.24172

10.1152/ajpgi.00186.2015

10.1136/gut.33.9.1249

10.1113/JP272613

10.1093/ajcn/61.4.792

10.1017/S0007114511007252

10.1093/ajcn/55.3.719

10.1038/ejcn.2016.248

10.1017/S0007114509991863

10.1074/jbc.M211609200

10.1016/j.tips.2009.09.001

10.1146/annurev-immunol-051116-052235

10.1016/j.neuroscience.2015.01.040

10.1074/jbc.M301403200

10.1074/jbc.C500213200

10.1016/j.jnutbio.2007.08.002

10.1093/jn/133.7.2485S

10.1139/O07-145

10.1038/mi.2014.44

10.1016/S0016-5085(82)80339-9

10.1111/j.1440-1746.2006.04213.x

10.1111/j.1440-1746.1992.tb00956.x

10.1136/gut.52.11.1572

10.1093/jn/135.4.837

10.1093/jn/136.1.70

10.1046/j.1440-1746.1999.01973.x

10.1053/gast.1996.v110.pm8566598

10.1002/iub.572

10.1042/BJ20150751

10.1079/BJN19870073

10.1136/gut.28.2.171

10.1177/0148607189013002109

10.3945/jn.113.182154

10.1007/BF01296816

10.1016/0016-5085(94)90166-X

10.1152/ajpgi.1997.272.4.G705

10.1053/gast.1997.v113.pm9247468

10.4162/nrp.2015.9.4.343

10.4049/jimmunol.1600165

10.1038/ni.3400

10.1152/ajpgi.00411.2015

10.1002/ijc.2910550329

10.1007/s10350-004-0810-x

Conley BA, 1998, Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors, Clin Cancer Res, 4, 629

10.1093/carcin/bgr254

10.1093/carcin/20.4.539

10.1053/gast.2001.22472

10.1371/journal.pone.0156334

10.1126/science.1160809

10.1016/j.molcel.2012.08.033

10.1016/j.cell.2014.04.051

10.1016/j.immuni.2013.12.007

10.3109/08820139.2015.1085389

10.1053/j.gastro.2013.04.056

10.1136/gut.47.3.397

10.1136/gut.37.4.536

10.1038/oncsis.2016.38

10.1038/ncomms7734

10.4110/in.2014.14.6.277

10.1084/jem.144.6.1674

10.1080/003655202317316105

10.1073/pnas.1322269111

10.1038/srep24838

10.1038/nature12726

10.1016/j.celrep.2016.05.047

10.1038/nature08530

10.1016/j.jnutbio.2010.07.009

10.1111/cmi.12720

10.1016/S0140-6736(04)15592-X

10.1053/j.gastro.2005.03.043

10.1038/nature12331

10.1126/science.1241165

10.1038/ncomms8320

10.1096/fj.14-268409

10.1136/gutjnl-2015-310022

10.3109/08820139.2015.1122613

10.1046/j.1365-2567.1997.00337.x

10.1023/A:1014781109498

10.1096/fj.00-0359fje

10.1016/j.nutres.2008.02.012

10.1016/j.jid.2016.11.014

10.1038/ni.3713

10.1038/mi.2016.114

10.1016/j.chom.2016.07.001

10.4049/jimmunol.1502046

10.1038/nm.3444

West NP, 2013, Butyrylated starch increases colonic butyrate concentration but has limited effects on immunity in healthy physically active individuals, Exerc Immunol Rev, 19, 102

10.3945/ajcn.116.146928

10.1038/nature12721

10.1016/j.immuni.2015.09.007

10.1002/art.39107

10.3945/ajcn.113.067629

10.1038/ncomms2852

10.1210/en.2015-1944

10.1042/CS20160263

10.1073/pnas.2637002100

10.1038/oby.2009.167

10.1038/nature05414

10.1038/sj.ejcn.1601857

10.1007/s00394-015-0985-z

10.2337/db11-1019

10.1074/jbc.M116.718460

10.1038/srep28159

10.1016/j.cell.2013.12.016

10.1038/nature18309

10.3945/ajcn.115.126706

10.1111/j.1471-4159.2009.05895.x

10.1038/ncomms4611

10.1073/pnas.1016088108

10.1161/CIRCULATIONAHA.116.024545

Natarajan N, 2015, Abstract 030: microbial short chain fatty acid (SCFA) metabolites lower blood pressure (BP) via endothelial g‐protein coupled receptor 41 (gpr41), Hypertension, 66, A030

10.1007/s00280-003-0580-5

10.1111/1750-3841.13725

10.1038/srep28797

10.1186/s40168-016-0178-x

10.1016/j.carbpol.2008.06.016

10.1093/ajcn/64.6.944

10.3945/jn.111.146464

10.1186/1475-2891-13-34

10.1093/jn/133.11.3523

10.1093/ajcn/86.4.1146

10.3945/ajcn.111.017228

10.1017/S0007114515001750

10.1111/apt.13749

10.1038/s41564-018-0123-9

10.1038/nbt.2845

10.1016/S0140-6736(80)91934-0

10.1056/NEJM198901053200105

10.1136/gut.40.4.485

10.1007/BF02071409

10.1046/j.1365-2036.1996.d01-509.x

10.1007/BF02049697

10.1042/cs0940671

10.1016/j.dld.2015.09.005

10.1016/j.clnu.2010.04.002

10.1007/s00384-013-1807-5

10.1111/j.1365-2036.2005.02639.x

10.1007/BF01300754

10.1111/j.1365-2036.1995.tb00386.x

10.1046/j.1365-2362.2003.01130.x

10.1023/A:1005537411244

10.1172/JCI111847

10.1111/1750-3841.12434

10.2337/diacare.27.1.281

10.1038/sj.ejcn.1602197

10.1093/jn/129.7.1492S

10.1097/00000441-199702000-00011

10.1111/j.1750-3841.2010.02031.x

10.1016/j.jada.2008.07.011

10.3390/nu7031992

10.1016/j.cmet.2015.05.012

10.1016/j.obmed.2017.03.002

10.1038/nm.3804

Thông tin
Thông tin xuất bản

Alimentary Pharmacology and Therapeutics

Tập 48 Số 1

15-34

Thông tin tác giả